Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OraSure Technologies, Inc.    OSUR

ORASURE TECHNOLOGIES, INC.

(OSUR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

OraSure Technologies : UPDATE - OraSure Technologies to Present at Raymond James 2019 Life Sciences and MedTech Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2019 | 05:04pm EDT

[Updated Release to Correct Date of Presentation]

BETHLEHEM, Pa., June 14, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Roberto Cuca, Chief Financial Officer, will speak to the investment community at the Raymond James Life Sciences and MedTech Conference. The conference will be simultaneously webcast over the Internet.

Mr. Cuca is scheduled to speak on Wednesday, June 19, 2019, at approximately 3:35 PM Eastern Time (12:35 PM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies' web site, www.orasure.com and clicking on the Investors link. A replay of the webcast will be available on OraSure Technologies' web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: http://wsw.com/webcast/rj115/osur/

About OraSure Technologies
OraSure Technologies is empowering the global community to improve health and wellness by providing access to accurate essential information. OraSure is a leader in the development, manufacture and distribution of point-of-care diagnostic tests, molecular collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform, sample self-collection and stabilization products for molecular applications, and oral fluid laboratory tests for detecting various drugs of abuse. Together with its wholly-owned subsidiaries (DNA Genotek, CoreBiome and Novosanis), OraSure provides its customers with value-added, end-to-end solutions that encompass tools, diagnostics and services. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Company contact:

OraSure Technologies, Inc.

Disclaimer

OraSure Technologies Inc. published this content on 14 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2019 21:03:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ORASURE TECHNOLOGIES, INC.
05:01pOraSure Technologies and Others Join Forces for HIV Testing Day
GL
06/14ORASURE TECHNOLOGIES : UPDATE - OraSure Technologies to Present at Raymond James..
PU
06/14UPDATE - OraSure Technologies to Present at Raymond James 2019 Life Sciences ..
GL
06/14ORASURE TECHNOLOGIES : to Present at Raymond James 2019 Life Sciences and MedTec..
AQ
06/13ORASURE TECHNOLOGIES : to Present at Raymond James 2019 Life Sciences and MedTec..
PU
06/13Orasure Technologies to Present at Raymond James 2019 Life Sciences and MedT..
GL
05/29ORASURE TECHNOLOGIES : to Present at Jefferies 2019 Healthcare Conference
PU
05/29OraSure Technologies to Present at Jefferies 2019 Healthcare Conference  
GL
05/23ORASURE TECHNOLOGIES INC : Change in Directors or Principal Officers, Submission..
AQ
05/15ORASURE TECHNOLOGIES : to Present at UBS Global Healthcare Conference
AQ
More news
Financials ($)
Sales 2019 173 M
EBIT 2019 18,9 M
Net income 2019 14,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 38,09
P/E ratio 2020 25,76
Capi. / Sales 2019 3,13x
Capi. / Sales 2020 2,92x
Capitalization 540 M
Chart ORASURE TECHNOLOGIES, INC.
Duration : Period :
OraSure Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORASURE TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 10,0 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Stephen S. Tang Chairman, President & Chief Executive Officer
Roberto E. Cuca Chief Financial & Accounting Officer
Michael Reed Chief Science Officer, SVP-Research & Development
Ronny B. Lancaster Independent Director
Charles W. Patrick Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ORASURE TECHNOLOGIES, INC.-25.00%540
MEDTRONIC PLC9.02%132 640
BAXTER INTERNATIONAL INC.24.17%41 696
HOYA CORPORATION24.44%28 508
ZIMMER BIOMET HOLDINGS12.51%23 900
TERUMO CORP-48.47%22 565